article thumbnail

Does the pandemic mark a turning point in vaccine development?

pharmaphorum

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.

article thumbnail

Building agile partner relationships at a vaccine-focused biotech

pharmaphorum

In this episode of the pharmaphorum podcast series, Dr Paul Tunnah chats with Jeff Baxter, CEO of VBI Vaccines and Lee Taurman, executive vice president full service commercial at Syneos Health. Jeff Baxter – President and CEO, VBI Vaccines. Mr. Baxter joined VBI in September of 2009.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths.

article thumbnail

Why pharma needs a revolution in culture

pharmaphorum

He was referring to his business’ share of misconduct related fines that, between 2009 and 2017, topped $342 billion across the US and Europe. It’s killing us.”

article thumbnail

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

pharmaphorum

She says she is “truly amazed” about what the industry has achieved in such a short time when it comes to innovations, vaccines and treatments. “When we come together like this, innovation can happen a lot faster.”. About the author.

Hospitals 111
article thumbnail

Ph. Eur. rabbit pyrogen test replacement texts ready for public consultation

European Pharmaceutical Review

Replacing the rabbit pyrogen test The texts covering topics such as vaccines for human use, blood products, antibiotics, radiopharmaceuticals and containers, have now been revised to replace the RPT with an in vitro alternative, the monocyte activation test (MAT) or another animal welfare-compatible approach. General chapter 2.6.30.

article thumbnail

Top 20 Radiopharma Companies Based on Market Cap

PharmaShots

Market Cap: $8.57M Founded Year: 2009 Total Employees: ~40 Headquarters: Oslo, Norway Stock Exchange: OSE Nordic Nanovector is a biotech company committed to developing and commercializing antibody-radionuclide conjugates to address significant unmet medical needs. In Aug’21, the US FDA cleared QSam’s IND application for CycloSam.

FDA 56